शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
FISCHERBSEFischer Medical Ventures Ltd· Healthcare Equipment & SuppliesHighPositive
Announced Wed, 9 Jul, 2025 · 15:54 IST

Fischer Medical Ventures Ltd has informed the exchange on the acquisition of a Landmark mixed use property in Malacca

Listed-company acquisitionStrategic Transactions View source PDFExplain this filing

FISCHER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
—Next day
—
prior close
₹839.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%—
Medical Equipment & Supplies peers, median of 11sector-2.2%—
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.3
10m
-4.2
15m
-5.7
30m
-5.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
—+0.4—-0.4—
Next day
—-0.1—-2.2—
2d
—+0.0—+0.2—
3d
—+1.2—-0.4—
4d
—+1.7—-2.1—
5d
—+2.0—-0.4—
1w
—+1.3—-2.8—
15d
—-1.3—-5.3—
1m
—-4.7—-2.3—
2m
—-1.9—-15.0—
3m
—-3.0—-18.4—
UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fischer Medical Ventures Ltd (BSE: 524743) has acquired a landmark mixed-use property in Malacca, Malaysia, located next to the well-known Mahkota Hospital. The property includes hotel, commercial, and retail components, which the company plans to progressively redevelop into an integrated healthcare hub featuring health screening centres, specialist clinics, and medical suites. The move is part of FMV's strategy to expand its presence across the Southeast Asian healthcare value chain and tap into medical tourism, with connectivity to Singapore, Indonesia, and the Philippines. The first phase of redevelopment is expected to begin later this year, subject to regulatory and planning approvals. No financial details of the deal (deal value, funding source, or seller) have been disclosed.

Likely market impact

This expansion into Malaysia signals a step beyond the company's core Indian medical device business into healthcare infrastructure and international markets, which could broaden long-term revenue streams but also exposes shareholders to execution, regulatory, and currency risks. No immediate impact on share price is expected as financial details remain undisclosed.